These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9661015)

  • 1. Entry of sanfetrinem into human polymorphonuclear granulocytes and its cell-associated activity against intracellular, penicillin-resistant Streptococcus pneumoniae.
    Cuffini AM; Tullio V; Bonino A; Allocco A; Palarchio AI; Carlone NA
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1745-50. PubMed ID: 9661015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sub-MICs of sanfetrinem promote the interaction of human polymorphonuclear granulocytes with a multiply resistant strain of Klebsiella pneumoniae.
    Cuffini AM; Tullio V; Palarchio AI; Bonino A; Carlone NA
    J Antimicrob Chemother; 1998 Aug; 42(2):249-52. PubMed ID: 9738845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clarithromycin mediated the expression of polymorphonuclear granulocyte response against streptococcus pneumoniae strains with different patterns of susceptibility and resistance to penicillin and clarithromycin.
    Cuffini AM; Tullio V; Mandras N; Roana J; Scalas D; Banche G; Carlone NA
    Int J Tissue React; 2002; 24(1):37-44. PubMed ID: 12013153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activity of sanfetrinem against isolates of Streptococcus pneumoniae and Staphylococcus aureus.
    Johnson AP; Warner M; Speller DC
    J Antimicrob Chemother; 1998 Nov; 42(5):643-6. PubMed ID: 9848449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of sanfetrinem and affinity for the penicillin-binding proteins of Streptococcus pneumoniae.
    Sifaoui F; Varon E; Kitzis MD; Gutmann L
    Antimicrob Agents Chemother; 1998 Jan; 42(1):173-5. PubMed ID: 9449281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postantibiotic effect of sanfetrinem compared with those of six other agents against 12 penicillin-susceptible and -resistant pneumococci.
    Spangler SK; Lin G; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2173-6. PubMed ID: 9333043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents.
    Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1997 Jan; 41(1):148-55. PubMed ID: 8980771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically enhanced 2000/125 mg co-amoxiclav to healthy volunteers.
    Alou L; Aguilar L; Sevillano D; Giménez MJ; Laguna B; Echeverría O; Carcas A; Lubomirov R; Casal J; Prieto J
    J Antimicrob Chemother; 2005 May; 55(5):742-7. PubMed ID: 15761068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced effects of amoxycillin/clavulanic acid compared with amoxycillin and clavulanic acid alone on the susceptibility to immunodefenses of a penicillin-resistant strain of Streptococcus pneumoniae.
    Cuffini AM; Tullio V; Ianni Palarchio A; Bonino A; Paizis G; Carlone NA
    Drugs Exp Clin Res; 1998; 24(4):173-84. PubMed ID: 10051963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of sanfetrinem (GV104326), a new trinem antimicrobial agent, versus Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
    Doern GV; Pierce G; Brueggemann AB
    Diagn Microbiol Infect Dis; 1996 Sep; 26(1):39-42. PubMed ID: 8950528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced killing of penicillin-treated gram-positive cocci by human granulocytes: role of bacterial autolysins, catalase, and granulocyte oxidative pathways.
    Isturiz R; Metcalf JA; Root RK
    Yale J Biol Med; 1985; 58(2):133-43. PubMed ID: 4036175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular uptake and intraphagocytic activity of the new fluoroquinolone AF 3013 against Klebsiella pneumoniae.
    Tullio V; Cuffini AM; Bonino A; Ianni Palarchio A; Rossi V; Carlone NA
    Drugs Exp Clin Res; 1999; 25(1):1-11. PubMed ID: 10337499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Investigation of the antibacterial activity of faropenem against Streptococcus pneumoniae].
    Hanaki H; Inaba Y; Hiramatsu K
    Jpn J Antibiot; 1999 Sep; 52(9):563-70. PubMed ID: 10746191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antibacterial activity of beta-lactams and non-beta-lactams against Streptococcus pneumoniae isolates from Sydney, Australia.
    Gosbell IB; Fernandes LA; Fernandes CJ
    Pathology; 2006 Aug; 38(4):343-8. PubMed ID: 16916725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model.
    Zhanel GG; Derkatch S; Laing N; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2007 Jan; 59(1):144-7. PubMed ID: 17079238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo antibacterial activities of sanfetrinem cilexetil, a new oral tricyclic antibiotic.
    Tamura S; Miyazaki S; Tateda K; Ohno A; Ishii Y; Matsumoto T; Furuya N; Yamaguchi K
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1858-61. PubMed ID: 9661036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae].
    Kawada H; Kitayama A; Fukuoka T; Ishii C; Abe T; Kakuta M; Domon H; Ohya S; Utsui Y
    Jpn J Antibiot; 1999 Aug; 52(8):533-40. PubMed ID: 10587878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of clarithromycin against penicillin-susceptible and penicillin-resistant strains of Streptococcus pneumoniae in a pharmacodynamic simulation model.
    Fuentes F; Sevillano D; Balcabao IP; Gómez-Lus ML; Prieto J
    J Chemother; 2000 Dec; 12(6):495-8. PubMed ID: 11154032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptor 2 deficiency delays pneumococcal phagocytosis and impairs oxidative killing by granulocytes.
    Letiembre M; Echchannaoui H; Bachmann P; Ferracin F; Nieto C; Espinosa M; Landmann R
    Infect Immun; 2005 Dec; 73(12):8397-401. PubMed ID: 16299338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of clavulanic acid and/or polymorphonuclear neutrophils on amoxicillin bactericidal activity against Streptococcus pneumoniae.
    Martín M; Gómez-Lus ML; Aguilar L; Martínez P; Giménez MJ; Prieto J
    Eur J Clin Microbiol Infect Dis; 1997 Jul; 16(7):512-6. PubMed ID: 9272386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.